| The Ministry of Health, the Regions, and AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 肝臟
> 肝臟疾病：大多數類型 | 監管合作夥伴關係
> 與監管機構合作 | 10,000 | National | Regularly | 115023591745 |
| Through submissions to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] via the Technical Health Committee of the Ministry of Health. | HIV
> HIV | 監管合作夥伴關係
> 與監管機構合作 | 1,000 | National | Regularly | 115050875230 |
| The organisation represents patients before national and European regulatory bodies, including AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and EMA [European Medicines Agency]. | 罕見
> 罕見疾病：代謝/溶酶體 | 監管合作夥伴關係
> 與監管機構合作 | 1,000 | National | Regularly | 115050896715 |
| Agenas [Agenzia Nazionale per i Servizi Sanitari Regionali – National Agency for Regional Health Services], Ministry of Health, Lazio Region. | 呼吸系統
> 呼吸系統：大多數狀況 | 監管合作夥伴關係
> 與監管機構合作 | 5,000 | National | Sometimes | 115052531440 |
| Yes. The association represents patients' interests before the institutions and regulatory authorities involved in decision-making processes related to healthcare policy, access to therapies, and the sustainability of the healthcare system. | 風濕性
> 風濕病：大多數類型 | 監管合作夥伴關係
> 與監管機構合作 | 100,000 | National | Regularly | 115057561938 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | 風濕性
> 風濕病：大多數類型 | 監管合作夥伴關係
> 與監管機構合作 | 100,000 | National | Regularly | 115057561938 |
| AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases. | 心臟
> 心臟衰竭 | 監管合作夥伴關係
> 與監管機構合作 | 10,000 | National | Regularly | 115057865983 |
| Approval of medicinal products by AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 呼吸系統
> 肺動脈高壓 | 監管合作夥伴關係
> 與監管機構合作 | 100 | National | Rarely | 115060569246 |
| Meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and Agenas [Agenzia Nazionale per i Servizi Sanitari Regionali – National Agency for Regional Health Services]. | 腎臟
> 腎臟疾病 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 1,000 | Regional | Sometimes | 114997535217 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], CNS [Consiglio Nazionale della Sanità - National Health Council], the Ministry, Parliament, the Regions, and regulatory bodies. | 免疫
> 原發性免疫缺陷病 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | National | Regularly | 115020417471 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 癌症
> 癌症：乳腺癌 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | We do not communicate with patients directly | National | Sometimes | 115035044046 |
| Letters were co-authored and submitted to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] at the request of paediatric nephrologists, seeking compassionate use authorisation for investigational medicinal products. | 罕見
> 罕見疾病：腎臟 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100 | National | Rarely | 115057369547 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | 風濕性
> 風濕病：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 115057561938 |
| We are members of the EMA [European Medicines Agency] multi-stakeholder advisory board, and we are frequently invited to participate in the scientific advice committee for the approval of medicines for mitochondrial diseases. | 罕見
> 罕見疾病：遺傳性 | 監管合作夥伴關係
> 為市場授權申請作出貢獻 | 100,000 | International | Regularly | 119078073632 |
| Our regional representatives participate in the regional diabetes technical working groups. | 內分泌
> 糖尿病（1型及2型） | 監管合作夥伴關係
> 參與臨床指引制定機構 | 10,000 | National | No | 115028521635 |
| We requested meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] on two occasions; one such request, in 2023, was successful. | 癌症
> 癌症：膽管 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100,000 | National | Rarely | 114996625156 |
| Meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and Agenas [Agenzia Nazionale per i Servizi Sanitari Regionali – National Agency for Regional Health Services]. | 腎臟
> 腎臟疾病 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 1,000 | Regional | Sometimes | 114997535217 |
| We request meetings with regional authorities and hospital management bodies responsible for pharmaceutical distribution. | 出血
> 出血性疾病：大多數類型 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100 | Regional | Sometimes | 114997584898 |
| Through meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] to safeguard the continued availability of medicines. | 罕見
> 囊性纖維化 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 10,000 | National | Regularly | 115005109524 |
| Through the Ministry of Health and the Lombardy Region. | HIV
> HIV | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 1,000 | Local | Regularly | 115006694528 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], CNS [Consiglio Nazionale della Sanità - National Health Council], the Ministry, Parliament, the Regions, and regulatory bodies. | 免疫
> 原發性免疫缺陷病 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 10,000 | National | Regularly | 115020417471 |
| We engage in dialogue with the Regional Authority and with the ASP [Aziende Sanitarie Provinciali – Provincial Health Authorities]. | 出血
> 血友病 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100 | Regional | Regularly | 115037242647 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 內分泌
> 糖尿病（1型及2型） | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100 | Local | Sometimes | 115037371533 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 神經系統
> 多發性硬化症 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100,000 | National | Regularly | 115038849633 |
| Through submissions to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] via the Technical Health Committee of the Ministry of Health. | HIV
> HIV | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 1,000 | National | Regularly | 115050875230 |
| The organisation represents patients before national and European regulatory bodies, including AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and EMA [European Medicines Agency]. | 罕見
> 罕見疾病：代謝/溶酶體 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 1,000 | National | Regularly | 115050896715 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | 風濕性
> 風濕病：大多數類型 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100,000 | National | Regularly | 115057561938 |
| The organisation [in Italy] actively engaged in challenging the withdrawal of a marketing authorisation for a medicinal product. It contributed to the submission of formal representations to the European Commission urging reconsideration of the withdrawal. | 罕見
> 罕見疾病：肝臟 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100 | National | Rarely | 115057832320 |
| AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases. | 心臟
> 心臟衰竭 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 10,000 | National | Regularly | 115057865983 |
| We collaborate with other patient associations of a similar nature to advocate for the approval and release of medicines required for our condition. | 癌症
> 癌症：血液 | 監管合作夥伴關係
> 與其他醫療倡導者 | 1,000 | National | Rarely | 115006753491 |
| Through the UNIAMO [Unione Italiana delle Associazioni di Malati – Italian Federation of Rare Disease Patient Organisations] Federation, with which we are affiliated. | 罕見
> 罕見疾病：大多數類型 | 監管合作夥伴關係
> 與其他醫療倡導者 | 100 | National | Regularly | 115055436186 |
| Through a network of associations. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 與其他醫療倡導者 | 100 | National | Regularly | 115057092350 |
| We are actively campaigning for the amendment or abolition of Nota 99 [Nota 99 is the Italian Medicines Agency (AIFA) reimbursement guideline for Chronic Obstructive Pulmonary Disease (COPD) maintenance therapies. It regulates the prescription of inhalers, ensuring appropriate diagnosis through spirometry while detailing which treatments GPs can initiate or repeat]. We are also campaigning for vaccination against Respiratory Syncytial Virus (RSV). | 呼吸系統
> 哮喘及慢性阻塞性肺病 | 影響政策及立法
> 影響醫療保健政策及立法 | 5,000 | National | Regularly | 114996865765 |
| Active participation in the drafting and approval of legislation in support of the disease area. | 一般健康
> 肥胖症 | 影響政策及立法
> 影響醫療保健政策及立法 | 10,000 | National | Regularly | 115012927513 |
| Cardiovascular Alliance — Ministry of Health. | 心血管
> 心血管：大多數類型 | 影響政策及立法
> 影響醫療保健政策及立法 | 100 | Regional | Sometimes | 115028352096 |
| By participating in regional and national policy-setting forums on rare diseases and skeletal dysplasia conditions more broadly. | 骨骼
> 骨骼：其他 | 影響政策及立法
> 影響醫療保健政策及立法 | 100 | National | Regularly | 115037246562 |
| Yes. The association represents patients' interests before the institutions and regulatory authorities involved in decision-making processes related to healthcare policy, access to therapies, and the sustainability of the healthcare system. | 風濕性
> 風濕病：大多數類型 | 影響政策及立法
> 影響醫療保健政策及立法 | 100,000 | National | Regularly | 115057561938 |
| By participating in regional and national policy-setting forums on rare diseases and skeletal dysplasia conditions more broadly. | 骨骼
> 骨骼：其他 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 100 | National | Regularly | 115037246562 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 內分泌
> 糖尿病（1型及2型） | 影響政策及立法
> 參與公眾聆訊及諮詢 | 100 | Local | Sometimes | 115037371533 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco - Italian Medicines Agency]. Relationship with regional health authorities. Reference clinical care pathways. Relationship with Ministries (Health, Welfare, Disability). | 神經系統
> 多發性硬化症 | 影響政策及立法
> 動員議員及政治領袖 | 100,000 | National | Regularly | 115038849633 |
| Cross-Party Parliamentary Group — IVT [Intravitreal Therapy] Technical Working Group. Cataract Technical Working Group — Regional Partnerships — Local Activities. | 視覺障礙
> 視覺障礙 | 影響政策及立法
> 動員議員及政治領袖 | 1,000 | National | Regularly | 115056238448 |
| Active participation in the drafting and approval of legislation in support of the disease area. | 一般健康
> 肥胖症 | 影響政策及立法
> 參與起草公共衛生法規 | 10,000 | National | Regularly | 115012927513 |
| AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases. | 心臟
> 心臟衰竭 | 影響政策及立法
> 處理醫療護理中的障礙/異常情況 | 10,000 | National | Regularly | 115057865983 |
| Market authorisation for "Koselugo" [used to treat neurofibromatosis type 1 (NF1)] should be extended to adult patients, given that it is currently approved only for paediatric cases where surgery is not an option. | 神經系統
> 神經纖維瘤病（NF） | 影響政策及立法
> 處理醫療護理中的障礙/異常情況 | 1,000 | National | Sometimes | 115060431887 |
| Organisation of educational camps, disease prevention, regulatory-compliant monitoring [in Italy], and waiting list management. | 未指定
> 未指定 | 定價及可負擔性倡議
> 追蹤及監測藥品定價／藥品短缺情況 | 100 | Local | Regularly | 115037563159 |
| Specifically at the level of the regional health authority, we have engaged in advocacy for the extension of the prescribability of Baqsimi (nasal glucagon) to be also reimbursable for adult diabetic patients. | 內分泌
> 糖尿病（1型及2型） | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 1,000 | Local | Sometimes | 115023236354 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 內分泌
> 糖尿病（1型及2型） | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 100 | Local | Sometimes | 115037371533 |
| Our work focuses on securing reimbursement for medicines, not on pricing. | 神經退行性
> 認知症 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 100,000 | National | Rarely | 115060441597 |
| Organisation of educational camps, disease prevention, regulatory-compliant monitoring [in Italy], and waiting list management. | 未指定
> 未指定 | 定價及可負擔性倡議
> 參與宣傳活動 | 100 | Local | Regularly | 115037563159 |
| Competitive tender for diabetes medical devices and supplies. | 內分泌
> 糖尿病（1型及2型） | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | Regional | Rarely | 114997517950 |
| We request meetings with regional authorities and hospital management bodies responsible for pharmaceutical distribution. | 出血
> 出血性疾病：大多數類型 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100 | Regional | Sometimes | 114997584898 |
| Through meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] to safeguard the continued availability of medicines. | 罕見
> 囊性纖維化 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 10,000 | National | Regularly | 115005109524 |
| We collaborate with other patient associations of a similar nature to advocate for the approval and release of medicines required for our condition [blood cancers]. | 癌症
> 癌症：血液 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | National | Rarely | 115006753491 |
| Extension of the indications for the use of Baqsimi, indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged one year and above with diabetes mellitus. | 內分泌
> 糖尿病（1型及2型） | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | Regional | Sometimes | 115021346889 |
| At the regional health authority level in particular, advocacy efforts were undertaken to extend the prescribability of Baqsimi (nasal glucagon) to include reimbursement for adult patients with diabetes. Additionally, participation in the competitive tendering process for diabetes medical devices and supplies — including reagent test strips, continuous glucose monitoring sensors, and insulin pumps — was pursued. | 內分泌
> 糖尿病（1型及2型） | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | Local | Sometimes | 115023236354 |
| At the regional health authority level in particular, advocacy efforts were undertaken to extend the prescribability of Baqsimi (nasal glucagon) to include reimbursement for adult patients with diabetes. Additionally, participation in the competitive tendering process for diabetes medical devices and supplies — including reagent test strips, continuous glucose monitoring sensors, and insulin pumps — was pursued. | 內分泌
> 糖尿病（1型及2型） | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | Local | Sometimes | 115023236354 |
| The association is at the forefront of efforts to ensure that all patients receive the appropriate therapy and that treatment is applied consistently at the national level. | 視覺障礙
> 視神經脊髓炎 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100 | National | Regularly | 115024933081 |
| Meetings with FG [Focus Group] to improve community-based diabetology services. | 內分泌
> 糖尿病（1型及2型） | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100 | Local | Sometimes | 115032223368 |
| We are seeking early access for the drug vorasidenib [oral cancer therapy for people with gliomas]. | 癌症
> 癌症：腦部 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100 | National | Sometimes | 115050882510 |
| Formal request letters to expedite access to medicines. | 癌症
> 癌症：婦科 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | National | Sometimes | 115055638865 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | 風濕性
> 風濕病：大多數類型 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100,000 | National | Regularly | 115057561938 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] or regional health authorities regarding delays in the market access of medicines. | 癌症
> 癌症：婦科 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | National | Rarely | 115060470442 |
| We are campaigning for vaccination against Respiratory Syncytial Virus (RSV) [in Italy]. | 呼吸系統
> 哮喘及慢性阻塞性肺病 | 改善存取途徑
> 倡導更廣泛的疫苗獲取途徑 | 5,000 | National | Regularly | 114996865765 |
| Specifically at the level of the regional health authority, we have engaged in advocacy for the extension of the prescribability of Baqsimi (nasal glucagon) to be also reimbursable for adult diabetic patients. | 內分泌
> 糖尿病（1型及2型） | 改善存取途徑
> 解決在獲取和管理方面的差距 | 1,000 | Local | Sometimes | 115023236354 |
| The association is at the forefront of efforts to ensure that all patients receive the appropriate therapy and that treatment is applied consistently at the national level. | 視覺障礙
> 視神經脊髓炎 | 改善存取途徑
> 解決在獲取和管理方面的差距 | 100 | National | Regularly | 115024933081 |
| We are an integral part of the Innovative Medicines Group of the Veneto Region [part of Veneto Region's governance structure for evaluating and managing access to innovative medicines]. | 癌症
> 癌症：血液 | 改善存取途徑
> 解決在獲取和管理方面的差距 | 1,000 | National | Regularly | 115053421236 |
| Regional disparities in access to treatment and enrolment in therapeutic management plans. | 神經系統
> 癲癇 | 改善存取途徑
> 解決在獲取和管理方面的差距 | 1,000 | Regional | Sometimes | 115063172483 |
| By participating in regional and national policy-setting forums on rare diseases and skeletal dysplasia conditions more broadly. | 骨骼
> 骨骼：其他 | 改善存取途徑
> 改善罕見/極罕見療法的獲取途徑 | 100 | National | Regularly | 115037246562 |
| Letters were co-authored and submitted to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] at the request of paediatric nephrologists, seeking compassionate use authorisation for investigational medicinal products [for rare kidney conditions]. | 罕見
> 罕見疾病：腎臟 | 改善存取途徑
> 改善罕見/極罕見療法的獲取途徑 | 100 | National | Rarely | 115057369547 |
| The organisation [in Italy] actively engaged in challenging the withdrawal of a marketing authorisation for a medicinal product. It contributed to the submission of formal representations to the European Commission urging reconsideration of the withdrawal. | 罕見
> 罕見疾病：肝臟 | 診斷及藥物送遞
> 確保安全有效地使用藥物 | 100 | National | Rarely | 115057832320 |
| Our regional representatives participate in the regional diabetes technical working groups. | 內分泌
> 糖尿病（1型及2型） | 診斷及藥物送遞
> 參與制定臨床指引 | 10,000 | National | No | 115028521635 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco - Italian Medicines Agency]. Relationship with regional health authorities. Reference clinical care pathways. | 神經系統
> 多發性硬化症 | 診斷及藥物送遞
> 參與制定臨床指引 | 100,000 | National | Regularly | 115038849633 |
| By participating in the regional coordination body that sits on the regional working table. | 內分泌
> 糖尿病（1型及2型） | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 100 | Regional | Rarely | 115019671886 |
| Regional health councillors, prescribing physicians, hospital pharmacists, regional drug directors, and representation at regional stakeholder forums. | 風濕性
> 風濕病：大多數類型 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 100,000 | National | Regularly | 115031446886 |
| We collaborate with institutional decision-makers, policymakers, and clinicians within a technical working group. | 內分泌
> 糖尿病（1型及2型） | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 100 | Local | Regularly | 115037426004 |
| We maintain regular contact with the relevant offices of the Tuscany Regional Authority. | 出血
> 血友病 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 100 | Regional | Regularly | 115043798242 |
| Represent patients before national and European regulatory bodies — including AIFA [Agenzia Italiana del Farmaco, the Italian Medicines Agency] and EMA [European Medicines Agency] — as well as national health institutions and local authorities. | 罕見
> 罕見疾病：代謝/溶酶體 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 1,000 | National | Regularly | 115050896715 |
| In an advisory capacity, when consulted by the local and regional health authority (Azienda Sanitaria Locale). | 內分泌
> 糖尿病（1型及2型） | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 100 | Local | Rarely | 115060756578 |
| We are members of the EMA [European Medicines Agency] multi-stakeholder advisory board, and we are frequently invited to participate in the scientific advice committee for the approval of medicines for mitochondrial diseases. | 罕見
> 罕見疾病：遺傳性 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 100,000 | International | Regularly | 119078073632 |
| By participating in the regional coordination body that sits on the regional working table. | 內分泌
> 糖尿病（1型及2型） | 機構管治
> 在多方持份者網絡中有效運作 | 100 | Regional | Rarely | 115019671886 |
| Participated alongside Public Institutions in the Stroke Observatory. | 腦血管
> 筆觸 | 機構管治
> 在多方持份者網絡中有效運作 | 5,000 | National | Regularly | 115019690819 |
| Participated alongside Public Institutions in the Stroke Observatory. | 腦血管
> 筆觸 | 機構管治
> 在多方持份者網絡中有效運作 | 5,000 | National | Regularly | 115019690819 |
| Regional health councillors, prescribing physicians, hospital pharmacists, regional drug directors, and representation at regional stakeholder forums. | 風濕性
> 風濕病：大多數類型 | 機構管治
> 在多方持份者網絡中有效運作 | 100,000 | National | Regularly | 115031446886 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 內分泌
> 糖尿病（1型及2型） | 機構管治
> 在多方持份者網絡中有效運作 | 100 | Local | Sometimes | 115037371533 |
| We collaborate with institutional decision-makers, policymakers, and clinicians within a technical working group. | 內分泌
> 糖尿病（1型及2型） | 機構管治
> 在多方持份者網絡中有效運作 | 100 | Local | Regularly | 115037426004 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco - Italian Medicines Agency]. Relationship with regional health authorities. Reference clinical care pathways. Relationship with Ministries (Health, Welfare, Disability). | 神經系統
> 多發性硬化症 | 機構管治
> 在多方持份者網絡中有效運作 | 100,000 | National | Regularly | 115038849633 |
| Healthcare protection, consumer protection, and other related areas. | 一般健康
> 醫療服務提供 | 維護病人權益／提升生活質素
> 保護/改善患者體驗 | 1,000 | Regional | Regularly | 115038525050 |
| Documentation requirements for the renewal of driving licences for individuals with diabetes. | 內分泌
> 糖尿病（1型及2型） | 維護病人權益／提升生活質素
> 保護/改善患者體驗 | Do not know | Regional | Sometimes | 115046244188 |
互動
行動與倡議
31 提及
